Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.900
-0.022 (-2.33%)
At close: Mar 6, 2026, 4:00 PM EST
0.918
+0.018 (1.97%)
After-hours: Mar 6, 2026, 7:10 PM EST
Aprea Therapeutics Stock Forecast
APRE's stock price has decreased by -65.9% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aprea Therapeutics stock have an average target of 5.50, with a low estimate of 4.00 and a high estimate of 7.00. The average target predicts an increase of 510.98% from the current stock price of 0.90.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aprea Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 1 | 1 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $11 → $7 | Buy | Maintains | $11 → $7 | +677.60% | Feb 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +344.35% | Jan 29, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $5 | Strong Buy | Maintains | $20 → $5 | +455.43% | Dec 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +2,121.73% | Jan 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +2,121.73% | Dec 17, 2024 |
Financial Forecast
Revenue This Year
299.54K
from 1.50M
Decreased by -80.06%
Revenue Next Year
102.00K
from 299.54K
Decreased by -65.95%
EPS This Year
-2.03
from -2.35
EPS Next Year
-1.20
from -2.03
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 315,000 | 315,000 | ||||
| Avg | 299,543 | 102,000 | ||||
| Low | 275,380 | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -79.0% | 5.2% | ||||
| Avg | -80.1% | -65.9% | ||||
| Low | -81.7% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.06 | -0.93 | ||||
| Avg | -2.03 | -1.20 | ||||
| Low | -1.99 | -1.63 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.